1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Diagnocure, Inc.

Diagnocure, Inc.

DGCRF
Diagnocure, Inc.US flagOther OTC
0.00
USD
- -
- -
21,520.00Market Cap
Diagnocure, Inc.
DGCRF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
TTM
FRC
0.01
0.05
0.05
0.03
0.19
0.15
0.12
0.06
0.05
0.04
0.03
0.03
0.06
0.02
0.01
0.01
0.16
Revenue per Share
-0.18
-0.17
-0.1
-0.11
-0.01
-0.09
-0.21
-0.24
-0.33
-0.3
-0.21
-0.03
-0.09
-0.08
-0.05
-0.08
0.06
Basic EPS, GAAP
-0.16
-0.18
-0.09
-0.1
- -
-0.13
-0.13
-0.2
-0.31
-0.28
-0.18
-0.06
-0.07
-0.04
-0.04
-0.03
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.15
-1.32
-1.04
-1.1
-1.09
-1.09
-1.29
-1.44
0.53
-1.92
-2.12
-2.14
-0.09
-0.17
-0.22
-0.3
-2.32
Book Value per Share
0.32
0.15
0.28
0.16
0.86
0.73
0.56
0.82
0.45
0.19
0.04
0.06
0.01
-0.04
-0.08
-0.11
0.01
Tangible Book Value per Share
19
19
27
29
31
34
34
38
42
43
43
43
43
43
43
43
43
Basic Weighted Avg Shares
- -
1
1
1
6
5
4
2
2
2
1
1
2
1
1
1
7
Sales/Revenue/Turnover
-1,511.35
-324.63
-200.17
-413.49
-11.64
-73.69
-170.91
-394.85
-693.92
-794.68
-422.46
-303.79
-151.97
-541.02
-376.88
-704.84
40.87
Operating Margin (%)
1
1
- -
- -
- -
- -
- -
1
2
2
1
1
1
1
- -
- -
- -
Depreciation Expense
-3
-3
-3
-3
- -
-3
-7
-9
-14
-13
-9
-1
-4
-4
-2
-4
3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,376.56
-337.95
-200.86
-416.39
-7.13
-60.38
-166.99
-402.91
-693.12
-796.27
-744.65
-101.83
-148.84
-531.41
-367.38
-698.56
41
Profit Margin (%)
5
2
7
4
13
18
12
24
10
13
7
7
5
4
2
1
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
6
3
8
5
27
25
20
40
30
23
15
14
10
7
5
1
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
126.55
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-5.24
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jan'16
Apr'16
Jul'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
6
- -
- -
Shares Outstanding
43
43
43
Market Capitalization
6
1
- -

Working Capital

FRC

•

in mil. unless spec.
Jan'16
Apr'16
Jul'16
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-16.54%
-32.67%
-70.96%
Free Cash Flow
-1.6%
-23.03%
-38.07%
Net Income, GAAP
31.06%
27.28%
77.16%
Sales/Revenue/Turnover
-11.37%
1.33%
-6.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
1
2015
- -
- -
- -
- -
1
2016
- -
6
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.01
-0.01
-0.01
- -
-0.05
2015
-0.01
-0.01
-0.01
- -
-0.08
2016
-0.01
0.13
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
Similar Companies
QuidelOrtho Corporation (0A55.L)
Seegene, Inc. (096530.KQ)
Span Divergent Limited (SDL.BO)
Novateor Research Laboratories (NOVATEOR.BO)
Curexo Inc. (060280.KQ)
Osang Healthcare Co.,Ltd (036220.KQ)
Business
DiagnoCure Inc. DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF), founded in 1998 and headquartered in Quebec City, Quebec, Canada, operates as a life sciences company focused on the development and commercialization of molecular and genomic diagnostic tests for cancer detection and management; its core products include the PROGENSA PCA3 assay for prostate cancer diagnosis, which detects prostate cancer-associated 3 gene expression in urine to aid decisions on repeat biopsies; the Previstage GCC colorectal cancer staging test utilizing guanylyl cyclase C markers to assess lymph node involvement; and related laboratory services supporting clinician decision-making in genitourinary and breast cancers. The company targets healthcare providers and patients primarily in North America and Europe, with operations centered in Canada and historical U.S. commercialization efforts through partnerships. In recent developments, DiagnoCure sold its PCA3 assets to Hologic Inc. Hologic, Inc. via Gen-Probe, enabling a special distribution to shareholders and a strategic pivot toward preserving liquidity through operational restructuring; it previously acquired high-value diagnostic tests for breast and colon cancer from Catalyst Oncology and established U.S. commercial operations to expand market reach.